A US clinical-stage vaccine company in San Carlos, California, whose 31-valent pneumococcal conjugate vaccine VAX-31 met every primary endpoint of its pivotal adult Phase III trial in October 2026, with a BLA planned for the first half of 2028 and $2.51 billion of cash to get there.
A US clinical-stage vaccine company in San Carlos, California, whose 31-valent pneumococcal conjugate vaccine VAX-31 met every primary endpoint of its pivotal adult Phase III trial in October 2026, with a BLA planned for the first half of 2028 and $2.51 billion of cash to get there.
